Yes, Rimegepant is FDA approved. The U.S. Food and Drug Administration (FDA) approved Rimegepant, under the brand name Nurtec ODT, on February 27, 2020. This medication belongs to the drug class of CGRP (calcitonin gene-related peptide) inhibitors.
Rimegepant is a prescription medication used for the acute treatment of migraines, with or without aura, in adults. Additionally, it is used to prevent episodic migraines. This medication helps alleviate symptoms such as headache, nausea, vomiting, and sensitivity to light and sound by blocking CGRP receptors.
Rimegepant works by targeting and blocking the CGRP receptors, which play a significant role in migraine pathophysiology. By inhibiting these receptors, Rimegepant helps reduce migraine symptoms and, when taken regularly, can decrease the frequency of migraine attacks.
Rimegepant is administered as an orally disintegrating tablet (ODT), which dissolves in the mouth without the need for water. The typical dosage is 75 mg, and the tablet should be taken as follows:
Common side effects of Rimegepant include:
Rimegepant can interact with other medications, affecting its efficacy and increasing side effects. Avoid taking Rimegepant within 48 hours of using the following:
Store Rimegepant at room temperature, away from moisture and heat. Keep it in its original blister pack until ready for use.
Rimegepant (Nurtec ODT) is an FDA-approved medication for the acute treatment and prevention of migraines in adults. Approved on February 27, 2020, it provides a quick-dissolving, effective option for managing migraine symptoms and reducing the frequency of episodic migraines. Always consult with a healthcare provider for personalized advice and follow all prescribed guidelines for safe and effective use.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!